StockTipsArenaBeta

BUY Aarti Drugs Limited — Siddharth Rai Mangala

BUYAarti Drugs Limited
Aarti Drugs share price target & all analyst calls

bySiddharth Rai MangalaHorizon: NA (inferred Swing (≤2wk))1 Sept 2026via Zee Business (Live)

Entry₹428Inferred
Target₹445
Total upside +3.97% (call closed)
Stop loss₹409-4.44% risk
At expiry₹426.915 Sept 2026, 3:30 pm
Expired-0.26%
Follow Siddharth Rai Mangala for new calls(29% target hit, 175 closed calls)Get alertsWatch AARTIDRUGS for new buy/sell callsGet alertsSee 130 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 15 Sept 2026
2 supporting1 neutral0 opposing
Supports the BUY call (2)

Aarti Drugs Ltd's Board of Directors has approved the company's Performance Stock Option Plan 2026. This plan is likely to incentivize employees and align their interests with the company's performanc

BSE · Board Meeting·27 Aug · 3w ago

(opens in new tab)

Aarti Drugs Targets 15-16% EBITDA Margin On Higher Sayakha Utilisation, Metformin Volumes: CFO

NewsNdtv-Profit·24 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (1)

The Board of Directors approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' to create and grant up to 8,00,000 stock options convertible into equity shares. This is subject to member

NSE · Outcome of Board Meeting·27 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aarti Drugs

All analyst calls on Aarti Drugs

More from Siddharth Rai Mangala

Every call and its outcome